FDA expands Juxtapid approval for pediatric patients aged 2 years and older with homozygous familial hypercholesterolemia to reduce plasma LDL-C levels.
12don MSN
Canadian pediatricians call for cholesterol checks for kids as young as 2 to catch heart risks early
The Canadian Paediatric Society is recommending cholesterol screening for all children between two and 10 years old, saying ...
Approval expands indication of JUXTAPID® to include children 2 years of age and older with HoFH. This announcement was made ...
Chiesi Global Rare Diseases’ lomitapide receives US FDA nod for paediatric use in homozygous familial hypercholesterolemia: Boston Thursday, March 5, 2026, 17:00 Hrs [IST] Chies ...
Amgen nears a 52-week high amid Middle East war, driven by Imdelltra sales growth and MariTide Phase 3 trials.
The Canadian Paediatric Society is recommending cholesterol screening for all kids between two and 10 years old.
Juxtapid has been available to treat adults with homozygous familial hypercholesterolemia (HoFH), a rare genetic disorder that causes extremely high levels of LDL cholesterol.
Inclisiran, an siRNA therapy, significantly reduces LDL-C by 28.5% in adolescents with heterozygous familial hypercholesterolemia (HeFH).
Opinion
Montreal Gazette on MSNOpinion
Labos: Cholesterol in kids: If you don’t look for it, you won’t find it
The Canadian Paediatric Society has issued a new position statement about the screening, diagnosis and management of cholesterol in children. Although the document covered many aspects of lipidology ...
Okay. Hi, everyone. Good morning. Thank you for joining us. I'm Jasmine Fels. I'm one of the biotech analysts here at Barclays, and we're very happy to have Editas Medicine here with us today. So we ...
A new preventive cardiology program at Robert Wood Johnson Medical School aims to stop heart disease before it starts.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results